Verendra kumar’s Post

Thanks, Richard! Today, I presented my recent results and insights on transcriptomic MYC activation in CLL. Long story short, high MYC transcriptomic activation is associated with increased interactions with the TME, suggesting MYC as an orchestrator of TME interactions and explaining why it is linked to various cellular processes. #eha #eha2024

Mark your calendars for a live webinar hosted by Fortis Institute of Blood Disorder on Innovations in Hematology. Join us on May 17th, 2024, from 7 PM to 8 PM and gain invaluable knowledge from leading specialists Dr. Jayastu Senapati and Dr. Nikhil M Kumar. Discover new technologies and innovative practices that are shaping the future of hematology. #AtFortisWeCare #FortisHealthcare #Webinar

NEW #Thalassemia Sessions from #ASH23🩸 💬 In this session, leading experts Maria Domenica Cappellini & Kevin Kuo discuss exciting updates in #thalassemia presented at the 2023 ASH Annual Meeting and Exposition The experts cover several topics, including the promise of novel #genetherapies, ongoing #clinicaltrials in the field, and the value of #precisionmedicine 🔬 Take a look 👉 https://lnkd.in/e2-JsM7Y #HemOnc #MPNsm American Society of Hematology

📢All 12 manuscripts in the #SpecialIssue “#Hematologic #Malignancies: Challenges from Diagnosis to Treatment”, led by Dr. Ioanna Sakellari and Dr. Eleni Gavriilaki, Hematology Department and Dr. Eleni Gavriilaki, have been published! 🎉🎉 📌You are welcome to read via the following link: https://lnkd.in/dyADYnGy

Lab Workup of Thalassemias Reference: Color Atlas of Hematology Book, 2nd edition

I have prepared a summary of an interesting topic I recently learned which is Hemophagocytic lymphohistiocytosis (HLH). It is one of the cases that I witnessed in the hematology laboratory🤩🔬.

Higher-risk #Myelofibrosis: Learn more about the selection and initiation of 2nd-line therapies for patients: New #CME #CE available on the Hematology Advisor Institute, powered by myCME. https://brnw.ch/21wGTM9

Have you read our recent Q&A with our Reach-the-World Fellow Mark Allan Lim? Learn more about his interest in improving the field of hematology in the Philippines here: https://lnkd.in/eqecTerN

NEW from #ASH2023 | CD33-TIM3 dual #CARTcells enhance specificity of #AML treatment 🎥 🩸 Marion Subklewe, MD, Ludwig-Maximilians-University of Munich, discusses the three main approaches and concepts within CAR T-cell therapy, highlighting her work on #CD33 and #TIM3 dual-targeting #CARTcells These cells are engineered to target only those cells expressing both the #CD33 and TIM3 #antigens, leading to an increase in specificty when treating #acutemyeloidleukemia (#AML) and allowing for the treatment of patients without the need for #allogeneic #stemcell #transplantation 💡 Give it a watch to learn more 👉 https://lnkd.in/eBWDW_ep #HemOnc American Society of Hematology #Leusm

New publication 📝 Retrospective analysis published in Hematology provides new insights for #AcuteLymphoblasticLeukemia, see: https://loom.ly/vnLhcDM #ALLsm #leusm #MedEducation